254 related articles for article (PubMed ID: 34981352)
1. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities.
Hagedorn HJ; Gustavson AM; Ackland PE; Bangerter A; Bounthavong M; Clothier B; Harris AHS; Kenny ME; Noorbaloochi S; Salameh HA; Gordon AJ
J Gen Intern Med; 2022 Nov; 37(14):3594-3602. PubMed ID: 34981352
[TBL] [Abstract][Full Text] [Related]
2. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
Miller WA; Gordon AJ; Clothier BA; Ackland PE; Bounthavong M; Garcia C; Kenny ME; Noorbaloochi S; Hagedorn HJ
Implement Res Pract; 2023; 4():26334895231199463. PubMed ID: 37790176
[TBL] [Abstract][Full Text] [Related]
3. Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention.
Gustavson AM; Kenny ME; Wisdom JP; Salameh HA; Ackland PE; Gordon AJ; Hagedorn HJ
Addict Sci Clin Pract; 2021 Aug; 16(1):51. PubMed ID: 34362445
[TBL] [Abstract][Full Text] [Related]
4. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
5. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
[No Abstract] [Full Text] [Related]
6. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
7. What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities.
Ackland PE; Kenny ME; Clothier BA; Salameh HA; Boening N; Gordon AJ; Noorbaloochi S; Gustavson AM; Miller W; Hagedorn HJ
J Gen Intern Med; 2023 Sep; 38(12):2647-2654. PubMed ID: 37037986
[TBL] [Abstract][Full Text] [Related]
8. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
9. Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration.
Gustavson AM; Wisdom JP; Kenny ME; Salameh HA; Ackland PE; Clothier B; Noorbaloochi S; Gordon AJ; Hagedorn HJ
Implement Sci Commun; 2021 Feb; 2(1):20. PubMed ID: 33588952
[TBL] [Abstract][Full Text] [Related]
10. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
11. Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care.
Chang ET; Oberman RS; Cohen AN; Taylor SL; Gumm E; Mardian AS; Toy S; Revote A; Lewkowitz B; Yano EM
J Gen Intern Med; 2020 Dec; 35(Suppl 3):918-926. PubMed ID: 33145686
[TBL] [Abstract][Full Text] [Related]
12. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
13. Impact of an intervention to implement provision of opioid use disorder medication among patients with and without co-occurring substance use disorders.
Frost MC; Malte CA; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
J Subst Use Addict Treat; 2023 Dec; 155():209175. PubMed ID: 37751798
[TBL] [Abstract][Full Text] [Related]
14. Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
Hawkins EJ; Danner AN; Malte CA; Blanchard BE; Williams EC; Hagedorn HJ; Gordon AJ; Drexler K; Burden JL; Knoeppel J; Lott A; Sayre GG; Midboe AM; Saxon AJ
Addict Sci Clin Pract; 2021 Sep; 16(1):55. PubMed ID: 34488892
[TBL] [Abstract][Full Text] [Related]
15. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
16. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
17. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
18. Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder.
Bart G; Korthuis PT; Donohue JM; Hagedorn HJ; Gustafson DH; Bazzi AR; Enns E; McNeely J; Ghitza UE; Magane KM; Baukol P; Vena A; Harris J; Voronca D; Saitz R
Addict Sci Clin Pract; 2024 Apr; 19(1):29. PubMed ID: 38600571
[TBL] [Abstract][Full Text] [Related]
19. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
[TBL] [Abstract][Full Text] [Related]
20. Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder.
Garcia CC; Bounthavong M; Gordon AJ; Gustavson AM; Kenny ME; Miller W; Esmaeili A; Ackland PE; Clothier BA; Bangerter A; Noorbaloochi S; Harris AHS; Hagedorn HJ
Implement Sci Commun; 2023 Aug; 4(1):91. PubMed ID: 37563672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
